Yazarlar : El-Najjar I1, Boumendil A2, Luan JJ
Yayın : Ann Oncol
Yayın Yılı : 2014
Pubmed Linki : http://www.ncbi.nlm.nih.gov/pubmed/25193988
Konu : Lenfoma
Literatür İçeriği :
Abstract
BACKGROUND:
The aim of this study was to investigate the impact of the high-dose regimen on the outcome of patients with follicular lymphoma(FL) having had autologous stem cell transplantation (ASCT) in a recent time period.
The aim of this study was to investigate the impact of the high-dose regimen on the outcome of patients with follicular lymphoma(FL) having had autologous stem cell transplantation (ASCT) in a recent time period.
PATIENTS:
Between 1995 and 2007, 2233 patients with FL had their first ASCT with either a total body irradiation-containing regimen (TBI) or BEAM, of which 47% were autografted in first remission.
Between 1995 and 2007, 2233 patients with FL had their first ASCT with either a total body irradiation-containing regimen (TBI) or BEAM, of which 47% were autografted in first remission.
RESULTS:
After a median observation time of 73 months (interquartile range 30-107), 5- and 10-year non-relapse mortality (NRM) was similar (6% and 10% in both groups). No significant NRM differences became evident after multivariate adjustment for confounders. Secondary malignancies were observed in 9.7% and 7.9% of the patients after TBI and BEAM (p=0.19), which were t-MDS/AML in 3.4% and 2.8% (p=0.57). The median time to t-MDS/AML was around 50 months in both groups. Because of a lower relapse incidence, TBI was associated with better event-free survival reaching statistical significance in the patients transplanted in first remission but not in those transplanted beyond first remission.
After a median observation time of 73 months (interquartile range 30-107), 5- and 10-year non-relapse mortality (NRM) was similar (6% and 10% in both groups). No significant NRM differences became evident after multivariate adjustment for confounders. Secondary malignancies were observed in 9.7% and 7.9% of the patients after TBI and BEAM (p=0.19), which were t-MDS/AML in 3.4% and 2.8% (p=0.57). The median time to t-MDS/AML was around 50 months in both groups. Because of a lower relapse incidence, TBI was associated with better event-free survival reaching statistical significance in the patients transplanted in first remission but not in those transplanted beyond first remission.
CONCLUSIONS:
In patients with FL who received TBI-based ASCT after 1995 increased NRM and t-MDS/AML risks did not emerge compared to BEAM whilst disease control was at least equivalent.
In patients with FL who received TBI-based ASCT after 1995 increased NRM and t-MDS/AML risks did not emerge compared to BEAM whilst disease control was at least equivalent.
| Sunumlar | Videolar | Olgu Tartışması |
